Fundraising FoxNovo Holdings
Family officeHellerup · Seed–Late Stage · 48 people tracked
Find your way into Novo Holdings
Sign up to see every warm intro you have to Novo Holdings
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Novo Holdings team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Novo Holdings serves as the stable owner of the Novo Group and seeks attractive long-term returns to fund the Novo Nordisk Foundation while growing its investment portfolio. A significant share of capital is directed to direct life science investing across seed, venture, growth, principal, planetary health and Asia strategies, spanning pharmaceuticals, biotechnology, medical technology, healthcare services and industrial biosolutions. It invests in both private and public companies, taking majority or minority positions with a flexible, long-term style. Beyond life sciences, its Capital Investments unit builds a diversified portfolio of equities, fixed income, real assets, credit and alternatives, partnering with specialist fund managers and investing for positive societal and environmental impact.
Source: firm website, verified Oct 17, 2026.
Team · 48 people
from the firm's website & curated & public directories
Aaron Nelson is a Partner in Novo Holdings' US Venture Investments unit, which he joined in June 2025. He was previously Managing Director at the Novartis Venture Fund, where he led Seed and Series A investments in therapeutic drug discovery, and contributed to Novartis's digital health investment program dRx Capital. Earlier he worked across Novartis Research & Development units including Trials of the Future and Investigative Toxicology. He holds a BA from Cornell University, a PhD in Cell and Microbiology from the University of Pennsylvania, and an MD from Tufts University, and conducted post-doctoral studies at the Karolinska Institutet.
Abhijeet Lele is Senior Partner and Head of US Principal Investments at Novo Holdings, which he joined in September 2020, with over 20 years of healthcare investment experience. He previously led US healthcare investing at Temasek and, before that, at Investor AB/Patricia Industries, and began his investing career at EGS Partners, a healthcare-focused hedge fund. Earlier in his career he was an Engagement Manager at McKinsey & Company and held operating roles in the pharmaceutical industry. He holds an MA in Natural Sciences from Cambridge University and an MBA from Cornell University.
Aleks Engel is a Partner in Novo Holdings' Planetary Health Investments team, based in Boston, having joined the firm in 2014 and previously worked on its Principal Investments and Seed Investments teams in Copenhagen. Before Novo Holdings, he held roles at Baxter International, Pfizer Global Research and Development, Thomson Scientific & Healthcare, and McKinsey & Company. He holds a PhD in Biochemical Engineering and an MSc in Chemical Engineering Practice from MIT.
Amer Sheikh joined Novo Holdings Seed Investments as a Partner in January 2026, where he leads the firm's Quantum Technologies investment strategy, covering quantum computing and sensing, advanced computing, and enabling software and infrastructure. He previously worked as an Investment Director at HSBC Ventures leading its Quantum and Deep Tech themes, and held senior investment roles at Sky Ventures and Centrica Ventures. He holds a PhD in Physics from Loughborough University and the Institut Laue Langevin and a BSc (Hons) in Physics.
Amit Kakar joined Novo Holdings Asia in August 2020 as Head of Asia, leading investments and partnerships across China, Japan, Singapore, and Southeast Asia. He has over 25 years of healthcare experience, previously holding roles at Everlife Asia (Head of M&A and Business Development), the Avenue Capital Group (Head of healthcare investments for Asia), and GE Healthcare. He holds a medical degree with a postgraduate qualification in Radiation and Nuclear Medicine from Tata Memorial Hospital and Cancer Centre in Mumbai, India.
Anders Bendsen Spohr joined Novo Holdings A/S in 2017 and serves as Managing Partner and Head of the Planetary Health Investments team. Before Novo Holdings, he held supply chain and operations leadership roles including VP of Global Product Supply at Xellia Pharmaceuticals, EVP of Global Product Supply at Leo Pharma, and VP of Global Supply Chain at Novozymes. He holds a PhD in Biotechnology and an MSc in Chemical Engineering from the Technical University of Denmark, along with a graduate diploma in Business Administration from Copenhagen Business School.
Andreas Nickelsen is a Partner in Novo Capital Investors at Novo Holdings, having joined in March 2022. He holds an MSc in Economics from the University of Copenhagen and became a CFA Charterholder in 2011. Before Novo Holdings, he worked at Realdania, Sampension, and Ørsted.
Anna Fan is a Senior Partner at Novo Holdings, where she leads the public investing strategy for the Venture Investments team and serves on the Life Sciences Operating Committee. Before joining the firm, she covered publicly traded biotech companies at Sectoral Asset Management and began her career in financial advisory serving fund managers and corporate clients in life sciences. She holds a Ph.D. and B.Sc. in Biochemistry from McGill University and is a CFA charterholder.
Managing Partner in Principal Investments and a member of the Executive and Life Science Leadership Teams.
Managing Partner in Capital Investments and a member of the Executive and Capital Investments Leadership Teams.
Camilla Petrycer Hansen is a Partner at Novo Holdings, where she works with the REPAIR Impact Fund. She focuses on early-stage life science investments.
Emmanuelle Coutanceau is a Partner in Seed Investments at Novo Holdings, focused on early-stage biotech investment and company creation. She has over 15 years of experience backing innovations from the laboratory to the clinic and has served as a board director on strategic, compensation, and governance committees.
Jørgen Søberg Petersen is a Senior Partner at Novo Holdings, where he has worked since 2017 on the venture capital team focused on building and scaling biotech companies. Trained as a physician-scientist in Denmark and the United States, he previously held R&D and leadership roles at Merck and Novo Nordisk and co-founded Zealand Pharma (NASDAQ: ZEAL.CO), where he served as Chief Scientific Officer. He has been a founding executive or investor in more than a dozen biotech companies, several of which have been taken public or sold.
Managing Partner of Novo Holdings' Seed Investments unit, emphasizing a hands-on approach to give promising projects and startups optimal conditions for success.
Max Klement is a Partner in Venture Investments at Novo Holdings. He has an engineering background and experience in the global biotech industry, focusing on the development and translation of biomedical science toward human health applications.
Hongjie Hu is a Partner in Growth Investments at Novo Holdings, where he focuses on investments at the intersection of healthcare, life sciences, and technology across North America, Europe, Israel, and Asia.
Alan Liu is a Principal in the Planetary Health Investments department at Novo Holdings A/S, which he joined in 2020, where he works on deal sourcing, execution, and portfolio management. Before Novo Holdings, he worked in J.P. Morgan's European Healthcare team in London and its North Asia M&A team in Hong Kong, handling private and public transactions across multiple industries. He holds a BSc in Quantitative Finance from CUHK, an MPhil in Biotechnology from Cambridge, and an MSc in Integrated Immunology from Oxford.
Anders Lykke Iversen joined Novo Holdings in November 2017 as an Associate in Principal Investments and works on deal sourcing, execution, and portfolio management. Before Novo Holdings, he was a management consultant at Bain & Company in Copenhagen, focusing on due diligence and post-acquisition work for private equity clients and strategy, performance improvement, and M&A for Nordic corporates. He holds a BSc in International Business and an MSc in Finance & Strategic Management from Copenhagen Business School.
Angela Jong joined Novo Holdings in 2025 as a Principal on the Planetary Health Investments team. She was previously a Vice President at Advent International working on healthcare buyout investments, and earlier worked at Stellar Health, a healthcare technology startup, and at TA Associates on healthcare growth and buyout investments. She started her career in investment banking at Morgan Stanley.
Daniel Rasmussen is a Principal at Novo Holdings, the investment company managing assets for the Novo Nordisk Foundation. He leads fund-of-funds and co-investment activities in biotechnology, quantum technology, and planetary health, and brings experience from roles at BASF Venture Capital, Verdane, and Oaklins across venture capital, growth equity, and corporate finance.
Alex Grooten works at Novo Holdings in the Finance & Operations department, serving as Senior Manager, Head of Accounting.
Álvaro Gallego Jurado joined Novo Holdings' People & Organisation department as a Rewards Manager in 2024, focusing on the governance of reward frameworks. He previously worked as a Performance & Rewards Partner Manager at Pandora A/S and gained earlier rewards experience at tech and security companies. A Spanish national, he holds an MChem in Chemistry and Materials Chemistry from the University of Edinburgh.
Amalie Stokkeland joined Novo Holdings A/S in February 2025 as a Senior Associate on the Planetary Health Investments team, where she works on deal sourcing, execution, and portfolio management. She previously worked in investment banking at ABG Sundal Collier on M&A and ECM transactions. She holds an MSc in Finance and a BSc in Economics and Business Administration from Aarhus University BSS.
Amy Kacprowicz works at Novo Holdings US Inc. within the Strategy and People department. She joined Novo Ventures (US), Inc. as an Office Manager in Boston, then moved to the People & Organization team as an HR coordinator supporting HR operations in the Boston and San Francisco offices in 2023. She holds a Bachelor of Arts from Hobart and William Smith Colleges and a graduate certificate in Human Resources from Northeastern University, following earlier roles in healthcare administration.
Andeta Jonuzaj joined Novo Holdings in 2021 as a compliance specialist, dividing her time between the Finance and Ventures teams. She previously spent 12 years in the banking sector, handling financial closing controls, compliance tasks including Know Your Client, and reporting of various statements. She holds a Master's degree in Financial Management.
Tax Manager within Finance & Operations.
Anne Dorte Stensberg Jensen joined Novo Holdings A/S as an Executive Assistant in the Principal Investments department in April 2024. She previously worked as a personal assistant at Copenhagen Infrastructure Partners and held PA and customer service roles at WS Audiology A/S. She holds a BA in German Business Communication from the University of Southern Denmark.
Barbara Fiorini is General Counsel at Novo Holdings A/S, which she joined in 2020, and has been part of the Executive Leadership Team since 2021, leading the legal department and handling the company's legal affairs across investments, divestments, and portfolio matters. She previously handled legal and compliance work for the Europe region at ISS World Services A/S and served as senior legal counsel at Genmab, including a period at Genmab US in New Jersey, and earlier worked as an M&A attorney at the law firm Plesner in Copenhagen. She holds a Master in Law from the University of Copenhagen and is a member of the Danish Bar Association.
Helle Bach joined Novo Holdings in 2025 as Chief People Officer, sitting within the Strategy & People organisation and on the Executive Leadership Team, and oversees the People & Organisation function across offices in Denmark, the US, London and APAC. She previously led the global HR function at DSV A/S, where she built the Group HR function and took part in company M&A, and earlier led the people area at Egmont International Holding after starting her career as a management consultant at Rambøll Management. She holds a Master of Political Science from Aarhus University (2001).
Kasim Kutay is CEO of Novo Holdings and emphasizes the firm's commitment to better healthcare and a greener future through investments in healthcare and bio-sustainability.
Kasper Jahn joined Novo Holdings in 2014 with the Principal Investments team, which handles healthcare buyout investments. He moved to lead the Strategy Office in 2021 and joined the Executive Leadership Team in 2025, taking on responsibility for People & Organisation. Before Novo Holdings, he was an Engagement Manager at McKinsey & Company in Copenhagen serving pharmaceutical and medical device companies, and he holds an MSc and PhD in Nanoscience from Aarhus University and is a CFA Charterholder.
Nigel Govett has served as Chief Financial Officer of Novo Holdings A/S since March 2022, and sits on the Board of Directors of NNIT A/S as Chair of its Audit Committee. He previously held CFO roles at Oman Infrastructure Investment Management and the Sovereign Wealth Fund of Oman, and director positions at EQT and Close Brothers. A UK national, he is a Fellow of the ACCA and holds a BA (Hons) in Historical Studies from the University of Sunderland.
General Partner at SOSV.
Kuang He is a biotech venture capitalist and board observer at Booster Therapeutics.
Peter Eckes is an operational partner at Astanor, which he joined in May 2023, where he works with the investment team and supports portfolio companies. He spent 32 years at BASF SE, including roles as CTO of its Agricultural Solutions R&D and Regulatory team and membership of the company's global Technology Leadership Team, with experience across agriculture, nutrition, specialty chemicals, and industrial biotechnology. His background covers R&D strategy, technology portfolio management, and large organizational transformations.
Heather Ludvigsen is Senior Manager of Venture Investments at Novo Holdings A/S. She holds a CPA credential and has worked in corporate audit, internal audit, and financial reporting across external and internal functions. Her experience encompasses investment fund accounting, regulatory compliance, budgeting, and process controls review.
What they invest in
from 125 of 137 portfolio companiesBiotech ×100Healthtech ×65Medical Devices ×47Deep Tech ×22AI & Machine Learning ×18Digital Health ×18New Materials ×10Hardware ×9
HQs:United States×58Denmark×13Germany×4United Kingdom×3Netherlands×3France×2
Who they back
founder profiles across 9 portfolio companiesFounding team size:solo founder×42 founders×43 founders×1
Investments · 137 tracked
founders shown can be your intro pathBy year:2026 · 102025 · 102024 · 102023 · 112022 · 102021 · 122020 · 52019 · 22018 · 12017 · 12016 · 12015 · 174 dated
AnaptysBio manages the financial collaborations from Jemperli (with GSK) and imsidolimab (with Vanda), operating a virtual model focused on protecting and returning royalty and milestone value to stockholders.
BiotechSan Diego, US
Robert Hoffman(Executive Officer)inMarco Londei(Executive Officer)inHamza Suria(Executive Officer, Director)inDaniel Faga(President, CEO, and Director)inChristopher Murphy(CFO)
BoardCarol Gallagher(Director)
Co-investorsBioBritFrazier Life SciencesBiotechnology Value FundNorwest Venture Partners
Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.
BiotechHealthtech
Lyn Baranowski(CEO)in
Co-investorsAndera PartnersCatalio Capital Management, LPF-Prime CapitalInVivium CapitalNorwest Venture PartnersPivotal Life Sciences+9 more
Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer.
BiotechHealthtechMedical DevicesSan Francisco, US
Dr. Edgar G. Engleman(Founder)
Co-investorsPfizer Venture InvestmentsPivotal Life SciencesRA CapitalSamsara BioCapitalSofinnova VenturesVivo Capital+3 more
Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.
BiotechCopenhagen, US
Garrett Winslow(Executive Officer)inLori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)Jennifer Jarrett(President, Chief Executive Officer and Director)inBecker Hewes(Chief Medical Officer)Sherwin Sattarzadeh(Chief Operating Officer)
Co-investorsAccess BiotechnologyViking GlobalAndreessen HorowitzBAM ElevateBay City CapitalCommodore Capital+8 more
Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.
BiotechHealthtech
John Quisel(Chief Executive Officer)inJean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)inPamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in
Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesForesite CapitalFrazier Life SciencesOrbiMed+7 more
Edgewise Therapeutics discovers and develops small molecule medicines targeting muscle proteins to treat neuromuscular and cardiac diseases, including sevasemten for muscular dystrophies and EDG-7500 for cardiomyopathy, leveraging a proprietary drug discovery platform based on muscle physiology and high-throughput functional assays.
BiotechDigital HealthBoulder, US
Kevin Koch(Executive Officer, Director)inAlan Russell(Director)inBadreddin Edris(Director and Co-Founder)inKenneth Harrison(Director)
BoardPeter Thompson(Director)inJonathan Root(Director)in
Co-investorsBoulder VenturesForesite CapitalOrbiMedUS Venture PartnersViking GlobalWellington Management+1 more
Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases.
BiotechHealthtechMedical DevicesNorthbrook, US
Jeffrey Aronin(Director)inJeffrey M. Dayno, M.D.(President and Chief Executive Officer)inPatrick Morris(Secretary and Treasurer)inRobert Repella(Director and Chief Executive Officer)Darien Parhad(Chief Financial Officer)
BoardAaron Royston(Director)in
Co-investorsAisling CapitalHBM Healthcare InvestmentsHBM PartnersParagon Biosciences LLCPivotal Life SciencesValor Equity Partners+3 more
Hemab develops targeted therapies for bleeding and clotting disorders such as Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and heavy menstrual bleeding.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsAccess BiotechnologyAvoro Capital AdvisorsHealthCapSofinnova PartnersRA Capital
MapLight Therapeutics is a biopharmaceutical company developing targeted treatments for central nervous system disorders through a platform designed to modulate neural circuits implicated in disease.
BiotechRedwood City, US
Anatol Kreitzer(Executive Officer)Kristopher Hanson(Executive Officer)James Lillie(Executive Officer)Jonathan Gillis(Executive Officer)inVishwas Setia(Executive Officer)inChristopher A. Kroeger(President, Chief Executive Officer and Director)
Co-investorsAvego BioScience CapitalPivotal Life SciencesForbion
Mirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases.
BiotechHealthtechSan Diego, US
Chris Peetz(Co-founder & Chief Executive Officer)inEric Bjerkholt(Executive Officer)inPeter Radovich(Executive Officer)in
BoardPatrick Heron(Director)inMichael Grey(Director)Timothy Walbert(Director)
Co-investorsChiesi VenturesFrazier Life SciencesLongitude CapitalMESA VERDE VENTURE PARTNERSNew Enterprise Associates (NEA)Pappas Capital+4 more
Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments.
BiotechHealthtechSouth San Francisco, US
Paul Hastings(Executive Officer, Director)inPaul H.inMatthew Plunkett(Executive Officer)in
BoardMichael Dybbs(Director)Jill Carroll(Director)inTiba Aynechi(Director)in
Co-investorsNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSR One Capital ManagementAmgen VenturesLogos+1 more
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies.
BiotechDigital HealthHealthtechMedical DevicesBoulder, US
Jason Leverone(Executive Officer)inSamuel Agresta(Executive Officer)inDylan Hartley(Executive Officer)inWendy Johnson(Executive Officer)Nicholas A. Saccomano(President and Chief Executive Officer and Director)
BoardIsaac Manke(Director)in
Co-investorsAccess BiotechnologyBoulder VenturesRiverVest Venture PartnersAbingworthACORN BIOVENTURESNew Enterprise Associates (NEA)
Praxis Precision Medicines is a central nervous system precision neuroscience biopharmaceutical company developing therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance, with a pipeline spanning movement disorders and epilepsy.
BiotechDeep TechHealthtechBoston, US
Steve Petrou(Co-Founder, President of Research & Development)inKiran Reddy(Executive Officer, Director)inMarcio Souza(President & Chief Executive Officer)in
BoardNicholas G. Galakatos(Director)in
Co-investorsAvoro Capital AdvisorsCapria VenturesOCV PartnersAlameda ResearchAPOLLO PROJECTSBlackstone+6 more
Recursion applies computational and data-driven approaches to biological science, aiming to accelerate drug discovery and develop new treatments.
AI & Machine LearningBiotechData & InfrastructureDeep TechMedical DevicesSalt Lake City, US
Chris Gibson(Co-founder and Chairman of the Board)inBlake C. Borgeson(Executive Officer, Director)inDean Y. Yi(Executive Officer, Director)Najat Khan(Chief Executive Officer)inNajat Khan, Ph.D.(CEO and President)inBlake Borgeson(Founder)
Co-investorsDCVC (Data Collective)Lux CapitalBaillie GiffordAdvantage Capital PartnersAir Street CapitalAmplify Partners+22 more
Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B).
BiotechHealthtechSouth San Francisco, US
Samir Gharib(Executive Officer)inRICHARD KING(Executive Officer, Director)inJavier Szwarcberg(Chief Executive Officer)in
BoardSimpson Camilla(Director)Tiba Aynechi(Director)inBali Muralidhar(Director)in
Co-investorsAisling CapitalHealthCapRiverVest Venture PartnersAbingworthNorwest Venture PartnersOmega Funds+1 more
Biomason uses biotechnology to grow biocement, producing concrete and tile products by using bacteria to bind natural materials as an alternative to Portland cement, aimed at concrete producers and the construction industry.
BiotechClimate TechConstruction TechNew MaterialsResearch Triangle Park, US
Ginger K. Dosier(Executive Officer, Director)inMichael F. Noel(Director)John M. Dosier(Executive Officer)Camilo Restrepo(CEO and President)in
Board seatAnders Bendsen Spohr· per SEC Form D
Co-investorsCarbonCelesta Capital
Acesion Pharma is a biotech company developing pharmaceutical treatments.
BiotechHealthtechMedical DevicesCopenhagen, DK
Ulrik Sørensen(COO & Co-founder)inMorten Grunnet(CSO & Co-founder)inAnders Gaarsdal Holst(CEO & CMO)inTorgeir Vaage(CFO)in
Co-investorsAlpha Wave GlobalCanaan PartnersBroadview VenturesGlobal BioAccess Fund
Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.
AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH
Thomas Baumert(Founder)inMark Pruzanski(Chief Executive Officer)inLuigi Manenti(Chief Medical Officer)inJon Freve(Chief Financial Officer)inBryan Yoon(General Counsel and Chief Administrative Officer)inAditya Venugopal(Chief Business Officer)in
Co-investorsAvego BioScience CapitalBioMedPartnersFrazier Life SciencesJeito CapitalLongitude CapitalOrbiMed+6 more
Altasciences operates a drug development platform that integrates nonclinical research, bioanalysis, manufacturing, and Phase I/II clinical execution to compress early-stage drug development timelines from industry standards of 27–51 months to as little as 18 months.
BiotechDeep TechEnterprise SoftwareHealthtechMedical DevicesLaval, CA
Marie-Hélène Raigneau(Chief Executive Officer)inCatherine Konidas(Chief Administrative Officer)inDr. Beatrice Setnik(Chief Scientific Officer)Dr. Gaetano Morelli(Executive Vice President Medical Affairs, Chief Medical Officer)Steve Mason(Co-Chief Operating Officer)inRobert Sabelli(Co-Chief Operating Officer)in
Co-investorsKilmer GroupSignet Healthcare Partners
Amass operates an agentic data platform that unifies over 500 million scientific documents — including research literature, patents, clinical trials, regulatory filings, and web sources — into a single engine that returns answers cited to their source.
AI & Machine LearningBiotechData & Infrastructure
Alexander Junge(Co-Founder & CTO)inHenrik Jensen(Co-Founder & CEO)in
Co-investorsGiant Ventures Global LlpKost Capital
AMSilk produces biotech-derived silk protein yarns for textile applications including fashion, accessories, and automotive interiors, using fermentation-based bioprocessing instead of traditional sericulture.
Advanced ManufacturingBiotechCircular EconomyCleantechNew MaterialsMunich, DE
Co-investorsAthosMIG Capital AG
AnaCardio is a Swedish clinical-stage biopharmaceutical company developing novel drugs to treat heart failure, with its lead program AC01 in phase 1b/2a clinical development.
BiotechHealthtechMedical DevicesStockholm, SE
Lars H. Lund(Founder)
Co-investors3B Future Health FundIndustrifondenPureos BioventuresSound Bioventures
AvenCell Therapeutics develops next-generation cell therapies for hard-to-treat cancers, including solid tumors, combining switchable universal CAR-T technology with a CRISPR/Cas9-based allogeneic platform.
BiotechLongevityMedical Devices
Andrew Schiermeier(Chief Executive Officer)in
Co-investorsBlackstone Life SciencesEight Roads VenturesF-Prime CapitalNYBC Ventures
BMK Genetics develops breeding programs and genetic solutions for salmon farming, offering tailored genetics for both sea-based open net-pen systems and land-based recirculating aquaculture systems.
AgTechBiotechFoodTechBergen, NO
Kristian Botnen(CEO)in
Booster Therapeutics develops small-molecule medicines that directly activate the cell's 20S proteasome to restore protein quality-control and clear disease-causing proteins, using its structure-based DGRADX platform combining high-throughput screening, X-ray crystallography, and computational tools.
BiotechDeep TechLongevity
Diogo R. Feleciano(Co-Founder & CSO)inDarci J. Trader(Scientific Co-Founder / Advisor)João Ribas(Interim-CBO)in
Co-investorsApollo Health VenturesKorify Capital
Breye Therapeutics is a biopharmaceutical company developing medicines for ophthalmologic and metabolic diseases, leveraging expertise in clinical development, manufacturing, and regulatory pathways.
BiotechMedical Devices
Ulrik Mouritzen(CEO)
Co-investorsSound Bioventures
Callio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment.
BiotechMedical DevicesSeattle, US
Piers Ingram(President, Co-Founder)inJerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)inZachary Hornby(Chief Executive Officer)
Co-investorsOmega FundsFrazier Life SciencesJeito CapitalNorwest Venture Partners
Chromologics is a Danish biotech company that uses a precision fermentation platform to produce natural food colours, marketed to food and beverage manufacturers as an alternative to synthetic colourants.
BiotechFoodTechNew MaterialsCopenhagen, DK
Anders Odum(Founder)inGerit Tolborg(Founder)inAnders Ødum(Co-founder & CTO)Klaus Bjerrum(CTO & Founder)inChristian H. Steffensen(CEO)inJens Bergholdt(CFO)in
Co-investorsBlue Horizon CorporationCollateral GoodDoehler VenturesNordic Foodtech VC
Clever Care is a culturally and linguistically sensitive Medicare Advantage health plan serving Southern California that integrates Eastern and Western medicine approaches.
HealthtechInsurTechSouthern California, US
Myong Sun Lee(Executive Officer, Director)Hiep Dinh Pham(Executive Officer, Director)Dave Firdaus(Executive Officer, Director)
Co-investorsGV (Google Ventures)Norwest Venture PartnersGlobal Founders CapitalAV8 VenturesFigure 8 InvestmentsPruVen Capital Partners+1 more
Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for gout, a chronic metabolic disease caused by elevated uric acid.
BiotechHealthtechMedical DevicesSan Diego, US
James Mackay(President & Chief Executive Officer)inNihar Bhakta(Chief Medical Officer)inAshwin Ram(Chief Operating Officer)inDeAnne Reid(Chief Administrative Officer)in
Co-investorsCatalys PacificAN Venture PartnersFrazier Life SciencesLightstone VenturesLongwood Fund
Elektrofi is a biotech company developing an ultra-high concentration microparticle formulation platform that enables subcutaneous delivery of biologic medicines such as monoclonal antibodies.
BiotechDeep TechHealthtechMedical DevicesBoston, US
Chase Coffman(Chief Executive Officer & Co-founder)inSam Huang(Director)Jason Norris(Co-founder)Charles L. Cooney(Director)Andrew Goldberg(Director)Constatine Chinoporos(Director)
Co-investorsBiotechnology Value FundCatalio Capital Management, LPCharlotte Angel FundGeneral CatalystRA CapitalSR One Capital Management+1 more
.png)
Engimmune develops soluble TCR therapeutic candidates using AI-guided innovation and protein engineering for oncology and immunotherapy applications.
AI & Machine LearningBiotechDeep Tech
Rodrigo Vazquez-LombardiinSai Reddyin
Co-investorsPureos Bioventures
Esco Lifesciences manufactures laboratory equipment, biopharma devices, and IVF medical equipment for clinical, research, and industrial laboratories across more than 100 countries.
Advanced ManufacturingBiotechHardwareHealthtechMedical DevicesSingapore, SG
Lim Lay Yew(Founder)inLow Yae Foong(Founder)
Co-investorsVivo CapitalGIC
Expedition Therapeutics is a drug development company focused on advancing therapeutic programs in areas such as CAR-T immunotherapy and oncology.
BiotechHealthtechMedical DevicesSan Francisco, US
Yi Larson(Founder and CEO)Geoff Gilmartin(Chief Medical Officer)Eric Hu(Chief Business Officer)
Co-investorsForbionSofinnova VenturesSanofi Ventures
LanzaTech converts carbon-rich gases from industrial sources like steel mills and landfills into fuels and chemicals using synthetic biology.
Circular EconomyCleantechClimate Tech
Dr. Jennifer Holmgren(CEO)Richard Forster(Founder)Sean Simpson(Founder)
Co-investorsActivant CapitalKhosla VenturesOutset VenturesQiming Venture PartnersSaints CapitalWestern Technology Investment+2 more
MedGenome provides genetic and molecular diagnostic testing across areas including reproductive care, rare hereditary conditions, oncology, and infectious diseases, and operates a CAP-accredited multiomics laboratory with high-throughput sequencing and a proprietary analytics platform.
BiotechDigital HealthHealthtechMedical DevicesBangalore, IN
Co-investorsSofinaATEL VenturesPeak XV PartnersLeapFrog Investments
MinervaX is a biotech company developing prophylactic vaccines, with therapeutic focus areas including immunology and infectious disease.
BiotechHealthtech
PerBengt(CSO)
Co-investorsAdjuvant CapitalIndustrifondenOrbiMedPureos BioventuresSanofi VenturesSunstone Capital+2 more
NMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions.
BiotechDeep TechHealthtechMedical DevicesAarhus, DK
Co-investorsJeito CapitalInkefRoche Venture FundLundbeckfonden Ventures
NorthSea Therapeutics is a clinical-stage biopharmaceutical company developing oral fatty acid-derived therapies for liver and metabolic diseases, including intestinal failure-associated liver disease (IFALD), severe hypertriglyceridemia, and MASH.
BiotechDigital HealthHealthtech
Co-investorsNew Science VenturesvenBio PartnersYsios CapitalBGVBioGeneration VenturesSofinnova Ventures+1 more
Revagenix is a precision-therapeutics company that develops drugs for serious chronic diseases, starting from the underlying biology and unmet clinical needs.
BiotechDeep TechHealthtechMedical Devices
Ryan Cirz(Co-founder & CEO)inAndrew McCandlish(Co-founder & COO)inPeter Smith(Chief Scientific Officer)inDaniel Cloutier(VP, Development)in
Co-investorsTenmile
Route 92 Medical develops neurointervention catheter systems and devices aimed at improving outcomes for neurovascular patients, including stroke treatment.
BiotechHardwareHealthtechMedical DevicesSan Mateo, US
Dr. Chou(Founder & Chief Executive Officer)Cindy Lynch(Executive Officer)inDr. Joey English(Chief Medical Officer)Tony Chou(Founder)in
BoardJack Lasersohn(Director)inTamir Meiri(Director)
Co-investorsThe Vertical GroupNorwest Venture PartnersRunway Growth CapitalUS Venture PartnersSectoral Asset ManagementSofinnova Ventures+1 more
Sonion designs and manufactures miniaturized audio components and solutions for hearing aids, including microphones, receivers, RIC systems, and sensors.
Deep TechHardwareHealthtechMedical DevicesRoskilde, VN
Co-investorsAltorTDF Ventures
Ritedose is a contract development and manufacturing organization (CDMO) that produces generic and specialty medications using advanced data analysis and custom technology solutions.
Advanced ManufacturingBiotechHealthtechMedical DevicesColumbia, US
Jody Chastain(Chief Executive Officer)in
Co-investorsOlympus Partners
THEVA manufactures high-temperature superconductor wire and related components for industrial, power transmission, and renewable energy applications.
Advanced ManufacturingDeep TechEnergyNew MaterialsGermany, DE
Co-investorsBayern KapitalEnBW New Ventures GmbHTarget Partners
Verana Health aggregates de-identified clinical data from a network of over 20,000 physicians in ophthalmology, urology, and neurology to power real-world evidence, clinical trial enablement, and quality reporting for pharmaceutical companies and healthcare providers using AI and machine learning.
AI & Machine LearningData & InfrastructureDigital HealthHealthtechSan Francisco, US
Mark Blumenkranz, MD(Co-Founder, Verana Health and Lagunita Biosciences)Sujay Jadhav(Chief Executive Officer)in
Co-investorsBreyer CapitalDeerfield Management CompanyGV (Google Ventures)Merck Global Health Innovation FundMSD Global Health Innovation FundNat Turner+3 more
ZELP develops technology to measure and reduce methane emissions from the livestock industry.
AgTechClimate TechImpact & Social GoodIoT
Francisco(Co-Founder, CEO)inPatricio(Co-Founder, Chairman of the Board)
Co-investorsCollaborative FundDanone Manifesto VentureStarlight Ventures
Revenue cycle management platform and electronic clearinghouse
HealthtechJacksonville, US
Nathan W. Eastman(Chief Financial Officer, Treasurer)inChristopher Hunter(Director)Steve Betts(Director)Earnie Franklin(Director)Aaron Gani(Director)Carl McDonald(Director)
Board seatAbhijeet Lele· per SEC Form D
Co-investorsFrancisco Partners
Genomatica (Geno) develops biotechnology processes to produce bio-based chemicals and materials—such as 1,4-butanediol (BDO), butylene glycol for cosmetics, and plant-based nylon—as alternatives to fossil-fuel-derived inputs.
BiotechCircular EconomyCleantechClimate TechNew MaterialsSan Diego, US
Christophe Schilling(Co-founder (former CEO))inBernhard Palsson(Co-founder)Carlos A. Cabrera(Executive Chairman)inJohn G. Gugel(Chief Executive Officer)inTom McDonald(SVP, Finance & Chief Financial Officer)inNelson Barton(SVP, Research and Development)in
Board seatAnders Bendsen Spohr· per SEC Form D
Co-investorsThule InvestmentsVantagePoint Capital PartnersViking GlobalCasdin CapitalDraper Fisher Jurvetson (DFJ)Mohr Davidow Ventures
MycoWorks produces Reishi, a premium biomaterial made from Fine Mycelium, used as a sustainable leather alternative in furniture, design, and automotive products.
BiotechCircular EconomyNew MaterialsEmeryville, US
Philip Ross(Founder)inMichael Lindheim(Executive Officer)Matthew Scullin(Executive Officer, Director)inEddie Pavlu(Founder)Phil Ross(Founder)Sophia Wang(Founder)
Board seatAnders Bendsen Spohr· per SEC Form D
Co-investorsATEL VenturesDCVC (Data Collective)GaingelsHemisphere Ventures LLCSOSVValor Equity Partners+9 more
__Twitter.png)
Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.
BiotechMedical DevicesCopenhagen, DK
Michael Pehl, MSc(Chief Executive Officer)
Co-investorsVida VenturesHealthCapJeito CapitalOrbiMedPontifax Venture CapitalRA Capital+3 more
AgNext is a deep-tech company that uses AI, diagnostics, and automation to make food quality measurable in real time, providing objective quality assessment and traceability across procurement, processing, and supply chains.
AgTechAI & Machine LearningFoodTech
Co-investorsAlpha Wave GlobalKalaari Capital
Antag Therapeutics develops GIP receptor antagonist therapies for obesity, diabetes, and overweight patients.
BiotechHealthtechCopenhagen, DK
Jens Juul Holst(Founder)Mette Rosenkilde(Founder)in
Co-investorsBroadview VenturesSR One Capital ManagementVersant Ventures
AnywhereCam sells solar-powered 4G/LTE cellular surveillance cameras with pan-tilt-zoom, two-way audio, night vision, and cloud storage that operate off-grid without wired power or Wi-Fi.
ConsumerE-commerceHardwareIoT
Michael Blecha(Founder)in
Co-investorsGreater Colorado Venture FundGeneral AtlanticHercules Capital, Inc.New Enterprise Associates (NEA)SoftBank GroupSoftBank Vision Fund+1 more
Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.
BiotechHealthtechGaithersburg, US
Han Lee(Executive Officer)Rami Elghandour(Executive Officer, Director)in
BoardJill Carroll(Director)inAli Behbahani(Director)inDerek Yoon(Director)inTiba Aynechi(Director)in
Co-investorsLG Technology VenturesNew Enterprise Associates (NEA)Quan CapitalSamsara BioCapitalSixty Degree CapitalSolasta Ventures+4 more
Asgard provides sales intelligence and intent detection data to B2B companies, identifying qualified prospects and their specific needs for targeted sales outreach and account-based marketing campaigns.
AI & Machine LearningData & InfrastructureEnterprise SoftwareSales TechParis, FR
Co-investorsTechstarsBoehringer Ingelheim Venture FundIndustrifondenRobot Ventures
Asgard Therapeutics develops direct cell reprogramming technologies that convert cancer cells into dendritic cells to restore anti-cancer immune responses.
AI & Machine LearningBiotechHealthtechMedical DevicesLund, SE
Cristiana Pires(Co-founder and CEO)inFábio Rosa(Co-founder and VP of Research)inFilipe Pereira(Co-founder and Head of Innovation)in
Co-investorsIndustrifondenLU InnovationRV Invest GmbHBoehringer Ingelheim Venture Fund
Augustine Therapeutics is a biotech company developing HDAC6-targeted therapies for peripheral neuropathies such as Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, as well as neurodegenerative disorders like ALS.
BiotechMedical Devices
Co-investorsAdBio partnersAsabys PartnersJeito CapitalPMVV-Bio VenturesNewton Biocapital
Bactolife develops Binding Proteins for use in functional foods for humans and in animal feed, aimed at supporting healthy digestion and livestock health.
AgTechBiotechFoodTech
Co-investorsCross-Border Impact Ventures
BBI Solutions provides reagents and biochemical products for in vitro diagnostics and life sciences teams, supporting assay development and diagnostic test manufacturing.
Advanced ManufacturingBiotechHealthtechMedical Devices
Alexander Socarrás(Group CEO)in
BioGeneration Ventures (BGV) is the early-stage arm of the Forbion-BGV platform of funds, investing in and supporting biotech and life sciences companies across their stages of development.
BiotechHealthtechNaarden, NL
Co-investorsBOMKfW CapitalEuropean Investment FundKfW
Biosyntia is a Copenhagen-based industrial biotech company that uses strain engineering and fermentation to produce sustainable, bio-based active ingredients like vitamin B7, replacing petrochemical-derived alternatives for cosmetics and nutrition markets.
Copenhagen, DK
Hans Genee(Founder)Morten Sommer(Founder)
Co-investorsEuropean Circular Bioeconomy FundSofinnova Partners
Bluejay is a biotechnology company focused on therapeutic development.
BiotechSan Mateo, US
Keting Chu(Founder, Chief Executive Officer and Chairman of the Board)inDajun Yang(Director)Nancy Hong(Director)inAlon Lazarus(Director)William J. Rutter(Director)Ting Jia(Director)
Co-investorsFrazier Life SciencesRA CapitalRiverVest Venture PartnersWellington ManagementFrazier Healthcare PartnersHBM Healthcare Investments+2 more
Activating the immune system to recognize and destroy tumor cells.
BiotechCambridge, US
Art Krieg(Executive Officer, Director)Barry Labinger(Executive Officer, Director)Chuck Abdalian(Executive Officer)David Mauro(Executive Officer)Karen Brennan(Executive Officer)Charles Yon(Executive Officer)
Co-investorsDecheng CapitalF-Prime CapitalLongitude CapitalSofinnova VenturesvenBio Partners
Cirius Therapeutics is a clinical-stage pharmaceutical company developing therapies for patients with chronic metabolic diseases driven by insulin resistance, including Type 2 Diabetes and obesity.
BiotechDigital HealthGrand Rapids, US
Jerry Callahan(Executive Officer)Brian Farmer(Executive Officer)inRobert Baltera(Executive Officer, Director)Howard Dittrich(Executive Officer)
BoardMichael Jandernoa(Director)Mark Olesnavage(Executive Officer)
Co-investorsFrazier Life SciencesFrazier Healthcare Partners
Claris Bio develops biologic therapies for sight-threatening eye diseases, with a current focus on bringing CSB-001, a novel treatment for patients with limbal stem cell deficiency, through clinical development and to market.
BiotechHealthtechMedical DevicesJersey City, US
Clarke Atwell(Co-Founder and Chief Operating Officer)inHenry Rath(Executive Officer)Susan Orr(Executive Officer)inStephen Brady(Executive Officer, Director)Michael Dybbs(Director)Matt Hobson(Director)
Co-investorsCatalio Capital Management, LPRA CapitalSofinnova VenturesCatalio Capital ManagementSamsara BioCapital
Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLАre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas.
BiotechHealthtechCambridge, US
Co-investorsCatalio Capital Management, LPCure VenturesVivo CapitalBrightEdgeCatalio Capital ManagementThird Rock Ventures
Coave Therapeutics develops targeted gene therapy vectors using its proprietary ALIGATER platform to deliver therapeutic genes to specific tissues with improved safety and precision.
BiotechDeep TechHealthtechMedical DevicesParis, FR
Co-investorsFund+Kurma PartnersSeroba Life SciencesV-Bio VenturesBpifranceGO Capital+2 more
Commit Biologics develops a complement-targeted drug discovery platform and antibody-based therapeutics for oncology, autoimmune diseases, and infectious disease indications.
BiotechHealthtechMedical DevicesAarhus, DK
Dennis(COO & Co-founder)Nick(Head of Discovery & Co-founder)Mikael(Head of Platform Technology & Co-founder)Heidi(Head of Drug Screening & Co-founder)Thomas(CEO)
Co-investorsKorysBioqube Ventures
Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies for complement-mediated diseases, with a lead AAV-based candidate (CTx001) for Geographic Atrophy secondary to Age-related Macular Degeneration.
BiotechDigital HealthHealthtechMedical DevicesMunich, DE
Rafiq Hasan(CEO and Managing Director)inMuhammad Ali Memon(Chief Medical Officer)in
Co-investorsBioGeneration VenturesCambridge Innovation CapitalGimvHadean VenturesSeroba Life SciencesBGV+2 more
Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.
AI & Machine LearningBiotech
Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)inMarie De Vulder(Chief Legal Officer Co-founder)inGuy Peeters(Chief Financial Officer Co-founder)inJohn-Paul Gallivan(Head of Development Co-founder)inFabrice Kolb(Head of Immunology Co-founder)inPieter Peeters(Operating & Technology Officer Co-founder)in
Co-investorsFinchley Healthcare VenturesLongwood FundLuma GroupSofinnova VenturesBAM ElevateForbion+2 more
Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters.
BiotechHealthtechCambridge, US
Kevin Mills(Executive Officer, Director)inRonald Goldstein(Executive Officer)inDonald Corcoran(Executive Officer, Director)inMarkus Renschler(Director)in
BoardTimothy Romberger(Director)Barry Mills(Director)
Co-investorsDroia VenturesLightstone VenturesOUP (Osage University Partners)Shah Family OfficeAlly Bridge GroupDe Novo Ventures+3 more
Doctor Anywhere is a technology-driven healthcare company that provides medical care to patients through online and in-person channels.
Digital HealthHealthtechMental Health
Lim Wai Mun(Founder)
Co-investorsOSK Ventures InternationalSquare Peg Capital
Draupnir Bio develops targeted protein degradation therapies using sortilin-based lysosome targeting chimeras to clear extracellular and membrane-bound protein aggregates in proteinopathies.
BiotechDeep TechMedical DevicesCopenhagen, DK
Simon Glerup(Professor)inCamilla Gustafsen(Professor)inPeder Søndergaard Madsen(Professor)Peter Seeberger(Professor)
Co-investorsInkefGilde HealthcareMC Healthcare Ventures
Droia Ventures is a specialist venture capital firm investing globally in early-stage drug development companies focused on therapeutics for oncology and genetic disease.
BiotechLeuven, BE
Co-investorsClavystBioFrazier Life SciencesLifeArc Ventures
Elo develops plant-based food ingredients and technologies to enhance nutritional value, taste, and climate resilience in everyday foods.
AgTechBiotechClimate TechFoodTechNew MaterialsDurham, US
ToddMichele Fite(Executive Officer)inMatthew Todd Rands(Executive Officer, Director)Chloe Pavely(Executive Officer)inMatt DiLeo(Director)inPaul Boyer(Executive Officer)in
Co-investorsDCVC (Data Collective)Accelr8DCVC BioKdT Ventures
Extracellular is a biomanufacturing company that helps cell-based product developers in cultivated meat, plant cell culture, and bioactives accelerate discovery, overcome production challenges, and commercialize their products.
Advanced ManufacturingBiotechFoodTechNew Materials
Will Milligan(CEO & Founder)in
Co-investorsBig Idea VenturesFFFNewland SyndicateUnruly Capital5AM VenturesAgent Capital+8 more
FIRE1 develops NORM, an implantable sensor placed in the inferior vena cava to directly measure fluid volume in heart failure patients, paired with a self-management platform to help patients engage with their own care.
Digital HealthHardwareMedical DevicesDublin, IE
Co-investorsAndera PartnersGimvIreland Strategic Investment FundLightstone VenturesLongitude CapitalNew Enterprise Associates (NEA)+5 more
Damora Therapeutics is a biotechnology company developing subcutaneous biologics as targeted, disease-modifying treatments for patients with mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis.
BiotechMedical Devices
Jennifer Jarrett(Chief Executive Officer & Board Director)inSherwin Sattarzadeh(Chief Operating Officer)inBecker Hewes(Chief Medical Officer)Garrett Winslow(General Counsel)inJim Baker(Chief Corporate Affairs Officer)inBrian Burkavage(Senior Vice President, Finance)in
Co-investorsEIR VenturesHadean VenturesM VenturesSEED Capital DenmarkSeventure PartnersSunstone Capital+3 more
Genome Medical provides telehealth-enabled genetic services, including genetic counseling, genetic testing, and clinical trial matching, with a focus on individuals with rare conditions.
BiotechDigital HealthHealthtechSouth San Francisco, US
Lisa Alderson(Executive Officer, Director)inRandal Scott(Director)Jill Davies(Executive Officer, Director)inElizabeth Moreno(Executive Officer)inMark Sylvester(Chief Financial Officer)inAndrew Warner(Vice President, Product)in
Co-investorsAlumni VenturesAvestria VenturesCanaan PartnersDreamers VCEcho Health VenturesGV (Google Ventures)+11 more
GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs.
BiotechHealthtechNewton, US
Ganesh V. Kaundinya(President & CEO)in
Co-investors5AM VenturesCatalio Capital Management, LPLifeArc VenturesRoche Venture FundSixty Degree CapitalSofinnova Partners+1 more
Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options.
BiotechSan Francisco, US
Agnes Rafalko(Executive Officer, Director)inSteven Axon(Chief Executive Officer)inHicham Alaoui(Chief Scientific Officer)inRose Marino(Chief Medical Officer)inPeter McWilliams(Chief Business Officer)Geoffrey Hird(Chief Technology Officer)in
Co-investorsAdvent Life SciencesAsahi Kasei Corporate Venture CapitalChiesi VenturesCTI Life Sciences Fund L.P.Mission Bay CapitalMission Biocapital+6 more
HepaRegeniX is a clinical-stage biotech company developing therapies that treat acute and chronic liver diseases by promoting liver regeneration.
BiotechHealthtechTuebingen, DE
Co-investorscoparionBoehringer Ingelheim Venture FundHTGF
Danish biotech developing non-opioid restorative treatments for chronic pain, hearing loss and sensory neuron disorders.
Co-investorsEIR VenturesIndaco Venture PartnersMedical Incubator Japan K.K.
HPNow produces hydrogen peroxide (Peroxide UltraPure) on-site through a patented electrochemical process that converts water, electricity, and air into low-concentration, high-purity peroxide for water treatment.
AgTechCircular EconomyCleantechHardwareNew Materials
Co-investorsAP VenturesEvonik Venture Capital GmbH
HST Pathways provides an all-in-one technology platform for ambulatory surgery centers (ASCs) that integrates clinical, financial, and operational management.
Digital HealthEnterprise SoftwareHealthtechSaaS
Gavin(Founder)
Co-investorsBain Capital Tech OpportunitiesBlue Hour VenturesBain Capital
OLG Machinery, founded in 2008, trades new and certified used industrial spare parts and machinery, serving U.S. companies operating across North and South America with a focus on Mexico.
Advanced ManufacturingB2B MarketplacesLogistics & Supply Chain
Co-investorsOxford Investment Opportunity Network (OION)Ally Bridge GroupAltium CapitalAmgen VenturesDroia VenturesFrazier Healthcare Partners+2 more
Hummingbird Bioscience is a precision biotherapeutics company developing a pipeline of novel targeted therapies for cancer, using proprietary drug discovery technologies and platforms.
AI & Machine LearningBiotechDeep TechHealthtech
Piers Ingram(Chief Executive Officer, Co-Founder, Executive Director)inJerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)inKonrad Paszkiewicz(Chief Technology Officer)inKwek Kon Yew(Chief Medical Officer)Dipti Thakkar(Chief Operating Officer)in
Co-investorsAltium CapitalClavystBioDecheng CapitalDroia VenturesFrazier Life SciencesKiwoom Investment+6 more
Inspirna is a clinical-stage biopharmaceutical company developing novel cancer drugs that target previously undruggable drivers of metastasis using its proprietary miRNA-DRIVEr platform.
BiotechHealthtechMedical DevicesNew York, US
Sohail Tavazoie(Co-Founder & Chair of Scientific Advisory Board)Masoud Tavazoie(Co-Founder & Advisor)in
Co-investorsSofinnova PartnersVivo CapitalSands Capital VenturesStart Capital
Inventiva is a clinical-stage biopharmaceutical company developing drug candidates, with a focus on liver and other diseases.
BiotechMedical Devices
Co-investorsEuropean Investment BankAndera PartnersClaret Capital PartnersNew Enterprise Associates (NEA)Samsara BioCapitalSofinnova Partners+1 more
Boston, US
Jurgen Horn(Executive Officer, Director)
BoardPhilip Austin(Director)in
Co-investorsF-Prime CapitalGV (Google Ventures)Anterra CapitalCasdin CapitalEight Roads Ventures
Kebotix uses artificial intelligence, machine learning, and laboratory automation to discover and develop new materials and molecules.
AI & Machine LearningDeep TechNew MaterialsCambridge, US
Dennis Sheberla(Executive Officer)inSemion Saykin(Executive Officer)Alan Aspuru-Guzik(Executive Officer)inAshish Kulkarni(Chairman and CEO)in
BoardTong Hui(Director)Andrew Krowne(Director)in
Co-investorsArcTern VenturesBantam GroupConstructor Capital USEmbark VenturesFlybridge Capital PartnersOne Way Ventures+6 more
Kivu Bioscience develops antibody-drug conjugate (ADC) therapeutics in clinical development, advancing a pipeline of cancer treatments through strategic partnerships and collaborations.
BiotechDeep TechHealthtechMedical Devices
Mohit Trikha(CEO)inSophia Randolph(Chief Medical Officer)in
Co-investorsBioGeneration VenturesBOMGimvHealthCapM VenturesRed Tree Venture
LAVA develops the Gammabody platform, which generates bispecific antibodies that activate gamma-delta T cells to treat cancer by directing immune cells to tumors and triggering anti-cancer immune responses.
AI & Machine LearningBiotechHealthtechMedical Devices
Ton AdanginHans van der Vliet(Head of Innovation)inSteve Hurly(Chief Executive Officer)Oxana Polyakova(Chief Scientific Officer)in
Co-investorsMRL Ventures FundSanofi VenturesYsios CapitalGilde HealthcareREDMILE
LimmaTech develops vaccine technologies and programs designed to combat antimicrobial-resistant pathogens and prevent severe infections.
AI & Machine LearningBiotechHealthtechMedical Devices
Co-investorsAdjuvant CapitalAndera PartnersTenmile
MDLIVE is a telehealth service offering 24/7 virtual medical appointments by phone or video with a national network of board-certified doctors, dermatologists, psychiatrists, and therapists.
Digital HealthHealthtechMental Health
Co-investorsGreat Oaks Venture CapitalHealth Velocity CapitalHeritage GroupPerot JainSixth StreetIndustry Ventures+1 more
Metagenomi is a genetic medicines company developing therapies based on gene editing technologies to treat patients with serious diseases.
BiotechDeep TechHealthtechMedical DevicesBerkeley, US
Brian Thomas(Founder)inBrian Thomas Jillian Banfield(Founder)Jill Banfield(Founder)Jian Irish(President and CEO)
BoardAndrew Farquharson(Director)inJak Knowles(Director)
Co-investorsCatalio Capital Management, LPRA CapitalSozo VenturesAgent CapitalFrazier Life SciencesHumboldt+5 more
Myricx Bio is a biotech company developing antibody drug conjugates (ADCs) based on N-myristoyltransferases (NMT) inhibitors for cancer treatment.
BiotechMedical DevicesLondon, GB
Co-investorsBrandon CapitalBrandon Capital PartnersSofinnova PartnersAbingworth
Nalu Medical develops a non-integrated neurostimulation system that uses electrical impulses to interrupt pain signals for patients with intractable chronic nerve pain.
HardwareHealthtechMedical DevicesCarlsbad, US
Earl Fender(President & CEO)inLee Hartley(Executive Officer)inAllen Meacham(Executive Officer)inBick Sellers(Executive Officer)inThomas A. West(Executive Officer, Director)inJeffrey Swiecki(Executive Officer)
Co-investorsAPERTURE Venture PartnersB Capital GroupB4 CapitalDecheng CapitalEndeavour VisionLongitude Capital+4 more
.jpeg){kind=logo}
BiotechBoston, US
David Donabedian(Executive Officer, Director)inRobert Hadfield(Executive Officer)inJohn McCabe(Executive Officer)in
BoardChristoph Westphal(Director)Ming Cheah(Director)inRaymond Camahort(Director)
Co-investorsDCVC (Data Collective)DCVC BioArkin CapitalLongwood Fund
Novo Nordisk is a pharmaceutical company that develops and markets treatments for conditions including diabetes, obesity/weight management, and haemophilia, with products such as GLP-1 therapies.
BiotechHealthtechCopenhagen, DK
Maziar Mike Doustdarin
Co-investorsHM Venture Partners
Numab develops multispecific antibody-based therapeutics using its proprietary λ-Cap and MATCH discovery and engineering platforms, aiming to improve on first-generation antibody therapies in potency, stability, effect duration, and safety.
BiotechDeep Tech
David Urech(Founder)in
Co-investorsEisai Innovation, Inc.HBM Healthcare InvestmentsHBM PartnersBiotechnology Value FundBlackRockForbion+1 more
Nuvig Therapeutics is a biotech company developing immune-modulating therapies for autoimmune and chronic inflammatory diseases, using an endogenous regulatory mechanism intended to treat inflammation without compromising broader immune function.
BiotechLongevity
Co-investorsSanofi Venturesabrdn plcAlexandriaB CapitalDigitalis VenturesGlobal BioAccess Fund+4 more
Octave is a mental health practice platform that connects licensed therapists with patients seeking in-network mental health care.
Digital HealthHealthtechMental HealthSaaSSan Francisco, US
Sandeep Acharya(Founder, CEO)inDavid White(Executive Officer)in
BoardSaurabh Bhansali(Director)inEllie Wheeler(Director)Craig Cimini(Director)
Co-investorsFelicis VenturesGreycroftHealthier CapitalNat TurnerObvious VenturesCompany Ventures+3 more
Orbis Medicines is a drug discovery company developing orally bioavailable macrocycle drug candidates as alternatives to injectable biologics, targeting both intracellular and extracellular protein targets.
AI & Machine LearningBiotechDeep Tech
Co-investorsNew Enterprise Associates (NEA)ForbionLilly Ventures
Oxford Biomedica is a biopharmaceutical contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, lentiviral vector technologies, and bioprocessing solutions.
Advanced ManufacturingBiotechDeep TechHealthtechMedical DevicesOxford, GB
Dr. Frank Mathias(Chief Executive Officer)inDr. Lucinda Crabtree(Chief Financial Officer)
BoardDr. Roch Doliveux(Non-Executive Chair)
Co-investorsOberland Capital
Teambit analyzes code, meeting time, and interactions to measure and improve the performance of software development teams, delivering objective metrics.
AI & Machine LearningDeveloper ToolsSaaS
Paula Enei(Founder)in
Co-investorsGG Capital4BIO CapitalDeerfield Management CompanyGeneral CatalystMRL Ventures FundNorwest Venture Partners
HealthtechHouston, US
Jonathan P. Otterstatter(Executive Officer, Director)Larry Lawson(Executive Officer, Director)John Untereker(Executive Officer)
BoardWilliam Taranto(Director)Joseph Volpe(Director)
Co-investorsArthur VenturesMerck Global Health Innovation FundSamsung Catalyst FundVivo Capital
Qure.ai builds deep learning and AI software to detect and manage diseases such as lung cancer, tuberculosis, pediatric TB, and stroke, with several FDA-cleared solutions.
AI & Machine LearningDigital HealthHealthtechMedical DevicesNew York, US
Prashant Warier(Founder)inPooja Rao(Founder)
Co-investorsCrane Venture PartnersHealthQuadLightspeed India PartnersLightspeed Venture PartnersMerck Global Health Innovation FundMSD Global Health Innovation Fund+6 more
Rappta Therapeutics develops small molecule compounds that reactivate protein phosphatase 2A (PP2A) to treat cancer by restoring the enzyme's tumor suppressor function.
AI & Machine LearningBiotechHealthtechMedical Devices
Co-investorsAdvent Life SciencesNovartis Venture Fund
Ray Therapeutics develops optogenetics gene therapy treatments for blinding diseases using advanced biotechnology.
BiotechDigital HealthHealthtechMedical Devices
Paul Bresge(Co-founder & Chief Executive Officer)
Co-investorsNorwest Venture Partners
Reunion Neuroscience is a clinical-stage biopharmaceutical company developing serotonergic psychedelic therapies for mental health conditions such as postpartum depression, adjustment disorder, and generalized anxiety disorder.
BiotechDigital HealthMental HealthMorristown, US
Sahil V. Kirpekar(President and CEO)inGregory Mayes(Executive Officer, Director)Ellen Lubman(Director)Mark Pollack(Executive Officer)inNathan Bryson(Executive Officer)inMark Theeuwes(Executive Officer)in
Co-investorsFemHealth VenturesMitsui Global InvestmentMPM BioImpactPalo Santo VC
Rondo Therapeutics is an immuno-oncology biopharmaceutical company developing bispecific/multispecific antibody therapeutics designed for tumor-selective targeting to treat solid tumors while sparing healthy tissue.
BiotechHealthtech
Shelley Force Aldred(Co-Founder & Chief Executive Officer)inNathan Trinklein(Co-Founder, President & CSO)inKatherine(Chief Development Officer)Thomas(Chief Medical Officer)
Co-investorsCanaan PartnersDementia Discovery FundRed Tree VentureSV Health InvestorsJohnson & Johnson Innovation – JJDC
Sidera Bio is a biotechnology company using human genetics to develop new medicines for patients.
Biotech
Co-investorsCatalio Capital Management, LPRA CapitalForbion
Sparrow Quantum develops quantum computing technology, building on research from the Niels Bohr Institute in Copenhagen where the company originated.
Deep TechHardwareQuantum ComputingCopenhagen, DK
Peter Lodahl(Founder)
Co-investorsLIFTTScale Capital2xNBalderton CapitalEuropean Investment Bank
Subra develops scalable superconductor solutions aimed at improving energy transmission and infrastructure.
CleantechDeep TechEnergy
Co-investorsEnBW New Ventures GmbH
Supira Medical develops a next-generation percutaneous ventricular assist device (pVAD) to provide temporary mechanical circulatory support for high-risk patients undergoing coronary interventions and those in cardiogenic shock.
HardwareHealthtechMedical DevicesCampbell, US
Nitin Salunke(President & CEO)inJean Orth(Executive Officer)Mariam Maghribi(Executive Officer, Director)
BoardCasey Gordon(Director)Christopher Shen(Director)Bihua Chen(Director)
Co-investors415 CapitalAmed VenturesThe Capital PartnershipUnorthodox VenturesQatar Investment Authority
Terremoto Biosciences is a clinical-stage biotech developing precision therapies for oncology and genetic diseases using lysine-targeted covalent chemistry.
BiotechDeep TechSouth San Francisco, US
Grace Lu(Executive Officer)James Christensen(Executive Officer, Director)Charles Baum(Executive Officer, Director)in
BoardMichael Goller(Director)Reid Huber(Director)inPeter Thompson(Director)in
Co-investorsEcoR1 CapitalOrbiMedRA CapitalThird Rock Ventures
The Protein Brewery develops FERMOTEIN, a fermentation-based whole food ingredient made from fungal mycelium that provides complete protein and prebiotic fiber.
BiotechFoodTechBreda, NL
Thijs Bosch(CEO)in
Co-investorsBOMUnovis Asset ManagementInvest-NL
Tribune Therapeutics is a preclinical biopharmaceutical company developing medicines that target CCN protein family signaling (such as CCN2/CTGF) to block fibrotic pathways.
BiotechHealthtech
Ole Kaasbøll(Co-founder)
Co-investorsHealthCapIndustrifondenInnovestor VenturesLifeArc VenturesInvestinor
WCG advances clinical trial efficiency and outcomes through research services and advisory support.
AI & Machine LearningBiotechDigital HealthEnterprise SoftwareHealthtechMedical DevicesSaaS
Co-investorsLeonard Green
Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases.
BiotechHealthtech
Co-investorsOrbiMedQuan CapitalRA CapitalSanofi VenturesSR One Capital ManagementJanus Henderson Investors+3 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AquafortusAristea TherapeuticsAvalynBGVBreye TherapeuticsExpedition TherapeuticsForYou MedicalManaT BioMenlo TherapeuticsOMass TherapeuticsRay TherapeuticsSiteOne TherapeuticsStargazer PharmaceuticalsSurya HospitalsWeight
Exits · 20
15 IPOs · 5 acquisitions · showing 18AnaptysBioNASDAQ: ANABAvalyn Pharma IncNASDAQ: AVLNBolt BiotherapeuticsNASDAQ: BOLTDamora TherapeuticsNASDAQ: DMRADisc MedicineNASDAQ: IRONEdgewise TherapeuticsNASDAQ: EWTXHarmony BiosciencesNASDAQ: HRMYHemab TherapeuticsNASDAQ: COAGMapLight TherapeuticsNASDAQ: MPLTMirum PharmaceuticalsNASDAQ: MIRMNkarta, Inc.NASDAQ: NKTXOnkure Therapeutics IncNASDAQ: OKURPraxisNASDAQ: PRAXRecursion PharmaceuticalsNASDAQ: RXRXSpruce BiosciencesNASDAQ: SPRBBluejaytxacq. by Mirum PharmaceuticalsLimmaTech Biologicsacq. by LillySiteOne Therapeuticsacq. by Eli Lilly and Company
Portfolio news
latest coverage across their companies
Novonesis · ad-hoc-news.de · Sep 6, 2026
Spruce Biosciences · stocktitan.net · Aug 12, 2026
Platanus · altss.com · Aug 11, 2026
Metagenomi · manilatimes.net · Aug 10, 2026
Praxis · marketbeat.com · Aug 6, 2026
Claris Bio · glance.eyesoneyecare.com · Aug 3, 2026
IPO stake values · per SEC filings · 12
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| AnaptysBio | 8.3% | $68.50 | Oct 2017 | $132.7M |
| Harmony Biosciences | 6.7% | $24.00 | Aug 2020 | $102.7M |
| Bolt Biotherapeutics | 13.0% | $20.00 | Feb 2021 | $90.1M |
| Edgewise Therapeutics | 10.4% | $16.00 | Mar 2021 | $79.4M |
| Hemab Therapeutics | 9.5% | $18.00 | May 2026 | $75.2M |
| Spruce Biosciences | 21.3% | $15.00 | Oct 2020 | $71.1M |
| Avalyn Pharma Inc | 8.0% | $18.00 | Apr 2026 | $59.9M |
| Mirum Pharmaceuticals | 9.6% | $20.00 | Jan 2020 | $48.9M |
| MapLight Therapeutics | 7.1% | $17.00 | Oct 2025 | $46.5M |
| Onkure Therapeutics Inc | 11.4% | $15.00 | Apr 2021 | $41.5M |
| Damora Therapeutics | 8.8% | $15.00 | Oct 2020 | $32.5M |
| Praxis | 3.3% | $18.25 | May 2021 | $26.3M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Novo Holdings made?
- Novo Holdings has 137 tracked investments, 20 of which have exited, including 24 dated in the last 24 months.
- What stage does Novo Holdings invest at?
- Novo Holdings invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is Novo Holdings's typical check size?
- Novo Holdings typically writes checks of $1.1M – $54M.
- What sectors does Novo Holdings focus on?
- Novo Holdings focuses on AgTech, Biotech, Cleantech, Climate Tech, Digital Health, Healthtech, Impact & Social Good, Longevity, Medical Devices, New Materials.
- Where is Novo Holdings located?
- Novo Holdings is headquartered in Hellerup, DK.
- Does Novo Holdings lead rounds?
- Yes, Novo Holdings leads investment rounds.
- Who does Novo Holdings co-invest with?
- Novo Holdings most often shares deals with Jeito Capital, Longitude Capital, Norwest Venture Partners, among 61 tracked co-investors.
Images
Co-investors · 11
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Abingworth is a life science venture capital firm that backs early-stage biopharma and biotech companies, helping entrepreneurs translate scientific discoveries into new therapeutics.
Roche Venture Fund is the corporate venture arm of Roche, investing in life science companies across pharmaceuticals, diagnostics and digital health to foster innovation and generate financial returns.
Bain Capital Life Sciences, founded in 2016, invests in biopharmaceutical, medical device, diagnostic, and life science tool companies globally, focusing on companies addressing unmet medical needs and driving medical innovation.
MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.
Apollo Health Ventures is a biotech-focused investor that combines traditional funding with venture building to back transformative healthcare and longevity companies in Europe and the US.
Brandon Capital is a life science venture capital firm investing in health and medical innovation companies, supporting them from proof-of-concept through to commercialisation.
Uncork Capital is a seed-stage venture firm that backs early founders, with a focus on AI-native companies driving scale and industry change.
Xfund is a venture capital partnership connecting leading VC firms with top research universities in the US and abroad, backing entrepreneurs with multidisciplinary backgrounds building technology companies.
JAZZ Venture Partners is a venture capital firm investing in early- and growth-stage companies at the intersection of technology, science, and human performance across enterprise, wellness, healthcare, and consumer markets.
6 Dimensions Capital is a healthcare-focused investment firm with offices in Boston, San Francisco, Hong Kong, and Shanghai. It backs healthcare startups and growth-stage companies operating in the U.S., Europe, China, Israel, and other markets, with an emphasis on life sciences businesses spanning China and the United States.
Firms observed investing alongside Novo Holdings, from public investor directories. Shared companies are the overlap with Novo Holdings's recorded portfolio.
Similar investors
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
Forbion is a global venture capital firm focused on advancing biotech innovations and other sustainable solutions aimed at improving human and planetary health.
Alumni Ventures (AV) is a venture capital firm that co-invests alongside lead VCs in startups, backing founders with capital and access to a large investor and operator community.
Obvious is a venture capital firm focused on supporting founders building solutions to humanity's largest challenges across planetary health, human health, and economic health.